Boston, MA -- (SBWIRE) -- 07/19/2013 -- Pfizer, Inc. was originally founded as fine chemicals business. Following a series of product developments and M&A deals the company is now present in 180 countries around the world, and its portfolio includes human and animal biologic, small molecule medicines, vaccines, nutritional and consumer products.

Features and benefits

- MarketLine Case Studies describe topics such as innovative products, business models, and significant company acquisitions.
- Fact-based and presented in an accessible style, they explain the rationale of commercial decisions and illustrate wider market and economic trends.

Highlights

In 2006, Pfizer sold its Pfizer Consumer Healthcare business to Johnson & Johnson for $16.6 billion. This division of the business included the company's OTC healthcare products and represented a departure from this market.
Pfizer Chairman and CEO Hank McKinnell described the decision to sell the Consumer Healthcare division as being an "important step to create value for our shareholders while transforming our company". He went on to describe how the strategy of the company had changed, with the plan being to focus on the core pharmaceutical business.
Following its departure from OTC Healthcare with the sale of its Consumer Healthcare division in 2006, just 3 years later Pfizer re-entered the market with its acquisition of Wyeth. The main reason for this shift back towards OTC healthcare has been the so-called "patent cliff".

View Full Report Details and Table of Contents

Your key questions answered

- How did Pfizer grow and diversify its business?
- Why did Pfizer sell its Consumer Healthcare division in 2006?
- Why did the company re-enter the OTC market?
- What share the OTC market did Pfizer hold before it sold the Consumer Healthcare division?
- What share the OTC market did Pfizer hold following its acquisition of Wyeth in 2009?

About Fast Market Research
Fast Market Research is an online aggregator and distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff will help you find the right research to fit your requirements and your budget. For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.

Browse all Pharmaceuticals research reports at Fast Market Research

You may also be interested in these related reports:

- Rx-to-OTC Switching Strategies - New Switching Opportunities in Weight Management and Smoking Cessation, but Encouraging the Uptake of Self-Medication Remains a Challenge
- Pfizer Limited (PFIZER) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
- Bristol-Myers Squibb Company (BMY) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
- Pfizer Japan Inc. - Pharmaceuticals & Healthcare - Deals and Alliances Profile
- Pfizer Canada Inc. - Pharmaceuticals & Healthcare - Deals and Alliances Profile
- Bayer HealthCare AG - Pharmaceuticals & Healthcare - Deals and Alliances Profile
- Healthcare, Regulatory and Reimbursement Landscape - Germany
- Bayer AG (BAYN) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
- Healthcare, Regulatory and Reimbursement Landscape - Norway
- Healthcare, Regulatory and Reimbursement Landscape - Turkey